title: EARLY CRT MONITORING USING TIME-DOMAIN OPTICAL COHERENCE TOMOGRAPHY DOES NOT ADD TO VISUAL ACUITY FOR PREDICTING VISUAL LOSS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL RANIBIZUMAB: A Secondary Analysis of Trial Data.
abstract: OBJECTIVE
  Our primary purpose was to assess the clinical (predictive) validity of central retinal thickness (CRT) and best corrected visual acuity (BCVA) at 1 week and 1 month after starting treatment with ranibizumab for central retinal vein occlusion. The authors also assessed detectability of response to treatment.
  
  
  METHODS
  The authors used data from 325 participants in the CRUISE study, which included measurement of time-domain CRT and BCVA at baseline, 1 week, 1 month, and 6 months postrandomization. Analysis of covariance models were fitted to assess clinical validity, and distributions of change were constructed to assess detectability of response.
  
  
  RESULTS
  There was no evidence that 1-week CRT, and very strong evidence that 1-week BCVA were associated with baseline-adjusted BCVA at 6 months (P = 0.17 and P < 0.001, respectively). There was strong evidence that both 1-month CRT and 1-month BCVA were associated with baseline-adjusted 6-month BCVA (P = 0.005 and P < 0.001, respectively), but simultaneous adjustment found evidence of independent association only for BCVA (P = 0.71 and P < 0.001 for CRT and BCVA, respectively). Detectability of response tended to be higher for CRT than BCVA at 1 week and 1 month but by 6 months these were equivalent for CRT and BCVA.
  
  
  CONCLUSIONS
  In this study, BCVA monitoring of treated central retinal vein occlusion patients seemed more informative than time-domain optical coherence tomography monitoring.
authors.affiliation: *Sydney School of Public Health, University of Sydney, Sydney, Australia; †Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Australia; ‡School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia; §Department of Health, Australian Government, Canberra, Australia; ¶Novartis Pharmaceuticals, Sydney, Australia; **Numerus Limited, Wokingham, United Kingdom; ††Numerus Limited, Tübingen, Germany; and ‡‡Westmead Institute, University of Sydney, Sydney, Australia.
authors.forename: Katy J L
authors.initials: KJ
authors.lastname: Bell
authors.forename: Andrew
authors.initials: A
authors.lastname: Hayen
authors.forename: Paul
authors.initials: P
authors.lastname: Glasziou
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Mitchell
authors.forename: Maria
authors.initials: M
authors.lastname: Farris
authors.forename: Jonathan
authors.initials: J
authors.lastname: Wright
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Duerr
authors.forename: Paul
authors.initials: P
authors.lastname: Mitchell
authors.forename: Les
authors.initials: L
authors.lastname: Irwig
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D011237:Predictive Value of Tests; D000069579:Ranibizumab / Q000627:therapeutic use*; D012160:Retina / Q000000981:diagnostic imaging / Q000473:pathology*; D012170:Retinal Vein Occlusion / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014786:Vision Disorders / Q000175:diagnosis* / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology*
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab